Literature DB >> 11023974

p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect.

M V Blagosklonny1.   

Abstract

Increasing the complexity of their models, p53s are stabilized either in order to function (wt p53) or due to the loss of function (mutant p53) with acquiring a mysterious prion-like ability to drive the normal p53 into the abnormal conformation to gain new functions. As already recognized, the loss of trans-activating function leads to a stabilization of mutant p53 because of the disappearance of the p53-inducible proteins, which otherwise directly (Mdm-2) or indirectly (p21) target p53 for degradation. Simplifying further, I will discuss that the loss of function results in a dominant-negative effect and gain-of-function (a dominant-positive effect). Thus, mutant p53 lacking trans-activation function nevertheless may retain the ability to repress transcription due to its competition with numerous transcription factors for their coactivators. When mutant p53 competes with wt p53, the inhibition of the wt p53-dependent transcription is perceived as a dominant-negative effect. Just like trans-repression, a dominant-negative effect requires an excess of p53 and, therefore, a 'dominant'-negative effect is not dominant. Furthermore, the stabilization of an endogenous mt p53 due to the loss of wt functions cannot occur in the presence of the wt p53 allele. Given the inability of mutant p53 to accumulate in the presence of wt p53, a dominant-negative effect does not naturally occur and, not surprisingly, heterozygous mt/wt cells are rare. The detection of a dominant-negative effect simply indicates that mutant p53 indeed has lost its function. Last, since mutant p53 loses some or most but not all activities and accumulates in the absence of wt allele, gain-of-function can be considered as an exaggeration of the remaining functions. Applications to cancer therapy are discussed. -Blagosklonny, M. V. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023974     DOI: 10.1096/fj.99-1078rev

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  47 in total

1.  ZBP-89 promotes growth arrest through stabilization of p53.

Authors:  L Bai; J L Merchant
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

2.  Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants.

Authors:  Samuel A Danziger; Jue Zeng; Ying Wang; Rainer K Brachmann; Richard H Lathrop
Journal:  Bioinformatics       Date:  2007-07-01       Impact factor: 6.937

Review 3.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

4.  From ENU mutagenesis to population genetics.

Authors:  N Avrion Mitchison; Bryan Clarke
Journal:  Mamm Genome       Date:  2008-03-26       Impact factor: 2.957

Review 5.  The role of biomarkers in the management of epithelial ovarian cancer.

Authors:  Wei-Lei Yang; Zhen Lu; Robert C Bast
Journal:  Expert Rev Mol Diagn       Date:  2017-05-15       Impact factor: 5.225

6.  Uterine Carcinomas in Tetrabromobisphenol A-exposed Wistar Han Rats Harbor Increased Tp53 Mutations and Mimic High-grade Type I Endometrial Carcinomas in Women.

Authors:  Janice B Harvey; Tanasa S Osborne; Hue-Hua L Hong; Sachin Bhusari; Tai-Vu Ton; Arun R Pandiri; Tiwanda Masinde; June Dunnick; Shyamal Peddada; Susan Elmore; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2015-09-08       Impact factor: 1.902

7.  Proteasome inhibitors suppress the protein expression of mutant p53.

Authors:  Marianna Halasi; Bulbul Pandit; Andrei L Gartel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis.

Authors:  Beng Hooi Phang; Rashidah Othman; Gaelle Bougeard; Ren Hui Chia; Thierry Frebourg; Choong Leong Tang; Peh Yean Cheah; Kanaga Sabapathy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

9.  Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junction.

Authors:  Franziska Pühringer-Oppermann; Michael Stahl; Gisela Keller; Mario Sarbia
Journal:  J Cancer Res Clin Oncol       Date:  2006-03-15       Impact factor: 4.553

Review 10.  Endocytosis and cancer.

Authors:  Ira Mellman; Yosef Yarden
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.